SPRINGWORKS THERAPEUTICS INC's ticker is SWTX and the CUSIP is 85205L107. A total of 79 filers reported holding SPRINGWORKS THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27,333,580 | -1.0% | 1,182,110 | +12.2% | 0.00% | 0.0% |
Q2 2023 | $27,614,021 | +29.5% | 1,053,166 | +27.1% | 0.00% | 0.0% |
Q1 2023 | $21,324,517 | +102411.9% | 828,458 | +3.6% | 0.00% | 0.0% |
Q4 2022 | $20,802 | -99.9% | 799,779 | +29.2% | 0.00% | 0.0% |
Q3 2022 | $17,657,000 | +28.6% | 618,894 | +11.0% | 0.00% | +50.0% |
Q2 2022 | $13,729,000 | -52.6% | 557,664 | +8.6% | 0.00% | -50.0% |
Q1 2022 | $28,971,000 | -5.1% | 513,308 | +4.3% | 0.00% | 0.0% |
Q4 2021 | $30,515,000 | -1.3% | 492,338 | +1.0% | 0.00% | 0.0% |
Q3 2021 | $30,922,000 | -25.5% | 487,436 | -3.2% | 0.00% | -33.3% |
Q2 2021 | $41,499,000 | +25.9% | 503,569 | +12.4% | 0.01% | +20.0% |
Q1 2021 | $32,969,000 | +12.0% | 448,134 | +10.4% | 0.01% | 0.0% |
Q4 2020 | $29,429,000 | +82.7% | 405,811 | +20.1% | 0.01% | +66.7% |
Q3 2020 | $16,106,000 | +61.7% | 337,874 | +42.4% | 0.00% | +50.0% |
Q2 2020 | $9,963,000 | +129.8% | 237,224 | +47.7% | 0.00% | +100.0% |
Q1 2020 | $4,336,000 | -57.2% | 160,613 | -39.0% | 0.00% | 0.0% |
Q4 2019 | $10,130,000 | – | 263,194 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 5,831,307 | $480,558,000 | 31.49% |
Consonance Capital Management LP | 1,199,339 | $98,838,000 | 11.90% |
Boxer Capital, LLC | 2,075,905 | $171,075,000 | 6.04% |
Perceptive Advisors | 9,699,824 | $799,362,000 | 5.19% |
Orbimed Advisors | 6,044,266 | $498,108,000 | 5.04% |
Samsara BioCapital, LLC | 169,852 | $13,998,000 | 1.73% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 1,375,775 | $113,378,000 | 1.50% |
SPHERA FUNDS MANAGEMENT LTD. | 195,117 | $16,080,000 | 1.09% |
Artal Group S.A. | 500,000 | $41,205,000 | 0.84% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 558,574 | $46,032,000 | 0.82% |